{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:29:10Z","timestamp":1793197750630,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011723","name":"Canton de Gen\u00e8ve","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The extent of SARS-CoV-2 circulation in many African countries remains unclear, underlining the need for antibody sero-surveys to assess the cumulative attack rate. Here, we present the results of a cross-sectional sero-survey of a random sample of residents of a health district in Yaounde, Cameroon, conducted from October 14 to November 26, 2020. Among the 971 participants, the test-adjusted seroprevalence of anti-SARS-CoV-2 IgG antibodies was 29\u00b72% (95% CI 24\u00b73\u201334\u00b71). This is about 322 times greater than the 0.09% nationwide attack rate implied by COVID-19 case counts at the time. Men, obese individuals and those living in large households were significantly more likely to be seropositive, and the majority (64\u00b72% [58\u00b77\u201369\u00b74]) of seropositive individuals reported no symptoms. Despite the high seroprevalence, most of the population had not been infected with SARS-CoV-2, highlighting the importance of continued measures to control viral spread and quick vaccine deployment to protect the vulnerable.<\/jats:p>","DOI":"10.1038\/s41467-021-25946-0","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T20:09:47Z","timestamp":1633637387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3245-4109","authenticated-orcid":false,"given":"Kene","family":"Nwosu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Wanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucien","family":"Mama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erol","family":"Orel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-5313","authenticated-orcid":false,"given":"Nicolas","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Meke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armel","family":"Tassegning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desire","family":"Takou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1836-442X","authenticated-orcid":false,"given":"Eric","family":"Mimbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josselin","family":"Guillebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Comte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4829-0935","authenticated-orcid":false,"given":"Laura","family":"Ciaffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"25946_CR1","unstructured":"AFP. WHO warns Africa is ill-equipped to deal with coronavirus due to \u2018weaker health systems\u2019. TheJournal.ie. https:\/\/www.thejournal.ie\/world-health-organisation-african-coronavirus-5017867-Feb2020\/ (2020)."},{"key":"25946_CR2","doi-asserted-by":"publisher","unstructured":"Umviligihozo, G. et al. Sub-Saharan Africa preparedness and response to the COVID-19 pandemic: a perspective of early career African scientists. Wellcome Open Res. https:\/\/doi.org\/10.12688\/wellcomeopenres.16070.2 (2020).","DOI":"10.12688\/wellcomeopenres.16070.2"},{"key":"25946_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533\u2013534 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"25946_CR4","doi-asserted-by":"publisher","first-page":"e002699","DOI":"10.1136\/bmjgh-2020-002699","volume":"5","author":"BZ Diop","year":"2020","unstructured":"Diop, B. Z., Ngom, M., Biyong, C. P. & Biyong, J. N. P. The relatively young and rural population may limit the spread and severity of COVID-19 in Africa: a modelling study. BMJ Glob. Health 5, e002699 (2020).","journal-title":"BMJ Glob. Health"},{"key":"25946_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0140-6736(20)31304-0","volume":"396","author":"S Stringhini","year":"2020","unstructured":"Stringhini, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet 396, 313\u2013319 (2020).","journal-title":"Lancet"},{"key":"25946_CR6","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","volume":"71","author":"J Zhao","year":"2020","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am. 71, 2027\u20132034 (2020).","journal-title":"Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am."},{"key":"25946_CR7","doi-asserted-by":"publisher","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science https:\/\/doi.org\/10.1126\/science.abf4063 (2021).","DOI":"10.1126\/science.abf4063"},{"key":"25946_CR8","doi-asserted-by":"publisher","unstructured":"Majiya, H. et al. Seroprevalence of COVID-19 in Niger State. medRxiv https:\/\/doi.org\/10.1101\/2020.08.04.20168112 (2020).","DOI":"10.1101\/2020.08.04.20168112"},{"key":"25946_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4269\/ajtmh.20-1235","volume":"104","author":"O Olayanju","year":"2021","unstructured":"Olayanju, O. et al. SARS-CoV-2 seropositivity in asymptomatic frontline health workers in Ibadan, Nigeria. Am. J. Trop. Med. Hyg. 104, 91\u201394 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"25946_CR10","doi-asserted-by":"publisher","unstructured":"Chibwana, M. G. et al. High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi. medRxiv https:\/\/doi.org\/10.1101\/2020.07.30.20164970 (2020).","DOI":"10.1101\/2020.07.30.20164970"},{"key":"25946_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.abe1916","volume":"371","author":"S Uyoga","year":"2021","unstructured":"Uyoga, S. et al. Seroprevalence of anti\u2013SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science 371, 79\u201382 (2021).","journal-title":"Science"},{"key":"25946_CR12","doi-asserted-by":"publisher","first-page":"e0242124","DOI":"10.1371\/journal.pone.0242124","volume":"15","author":"WA Halatoko","year":"2020","unstructured":"Halatoko, W. A. et al. Prevalence of SARS-CoV-2 among high-risk populations in Lom\u00e9 (Togo) in 2020. PLoS ONE 15, e0242124 (2020).","journal-title":"PLoS ONE"},{"key":"25946_CR13","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1016\/S2214-109X(21)00053-X","volume":"9","author":"LB Mulenga","year":"2021","unstructured":"Mulenga, L. B. et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. Lancet Glob. Health 9, e773\u2013e781 (2021).","journal-title":"Lancet Glob. Health"},{"key":"25946_CR14","doi-asserted-by":"publisher","unstructured":"Milleliri, J. M. et al. SARS-CoV-2 infection in Ivory Coast: a serosurveillance survey among gold mine workers. medRxiv https:\/\/doi.org\/10.1101\/2021.01.27.21249186 (2021).","DOI":"10.1101\/2021.01.27.21249186"},{"key":"25946_CR15","unstructured":"United Nations, Department of Economic and Social Affairs. World Population Prospects. https:\/\/population.un.org\/wpp\/ (2021)."},{"key":"25946_CR16","doi-asserted-by":"publisher","unstructured":"Chen, X. et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob. Health https:\/\/doi.org\/10.1016\/S2214-109X(21)00026-7 (2021).","DOI":"10.1016\/S2214-109X(21)00026-7"},{"key":"25946_CR17","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3201\/eid2611.202736","volume":"26","author":"MS Petersen","year":"2020","unstructured":"Petersen, M. S. et al. Seroprevalence of SARS-CoV-2-specific antibodies, Faroe Islands. Emerg. Infect. Dis. 26, 2761\u20132763 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"25946_CR18","doi-asserted-by":"publisher","unstructured":"Mohanan, M., Malani, A., Krishnan, K. & Acharya, A. Prevalence of SARS-CoV-2 in Karnataka, India. JAMA https:\/\/doi.org\/10.1001\/jama.2021.0332 (2021).","DOI":"10.1001\/jama.2021.0332"},{"key":"25946_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15010-020-01509-1","volume":"49","author":"D Wolff","year":"2021","unstructured":"Wolff, D., Nee, S., Hickey, N. S. & Marschollek, M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection 49, 15\u201328 (2021).","journal-title":"Infection"},{"key":"25946_CR20","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 5, 1598\u20131607 (2020).","journal-title":"Nat. Microbiol"},{"key":"25946_CR21","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa2006100","volume":"382","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson, D. F. et al. Spread of SARS-CoV-2 in the icelandic population. N. Engl. J. Med. 382, 2302\u20132315 (2020).","journal-title":"N. Engl. J. Med."},{"key":"25946_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41385-020-0303-9","volume":"13","author":"A Fischer","year":"2020","unstructured":"Fischer, A. Resistance of children to Covid-19. How? Mucosal Immunol. 13, 563\u2013565 (2020).","journal-title":"Mucosal Immunol."},{"key":"25946_CR23","doi-asserted-by":"publisher","unstructured":"Menachemi, N. Population point prevalence of SARS-CoV-2 infection based on a statewide random sample\u2014Indiana, April 25\u201329, 2020. MMWR Morb. Mortal Wkly. Rep. https:\/\/doi.org\/10.15585\/mmwr.mm6929e1 (2020).","DOI":"10.15585\/mmwr.mm6929e1"},{"key":"25946_CR24","doi-asserted-by":"publisher","first-page":"e0245556","DOI":"10.1371\/journal.pone.0245556","volume":"16","author":"FS Vahidy","year":"2021","unstructured":"Vahidy, F. S. et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: cross-sectional analysis from a diverse US metropolitan area. PLoS ONE 16, e0245556 (2021).","journal-title":"PLoS ONE"},{"key":"25946_CR25","first-page":"223","volume":"5","author":"O Byambasuren","year":"2020","unstructured":"Byambasuren, O. et al. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. J. Assoc. Med. Microbiol. Infect. Dis. Can. 5, 223\u2013234 (2020).","journal-title":"J. Assoc. Med. Microbiol. Infect. Dis. Can."},{"key":"25946_CR26","unstructured":"World Bank Open Data. Data. https:\/\/data.worldbank.org\/ (2021)."},{"key":"25946_CR27","doi-asserted-by":"publisher","first-page":"n334","DOI":"10.1136\/bmj.n334","volume":"372","author":"L Mwananyanda","year":"2021","unstructured":"Mwananyanda, L. et al. Covid-19 deaths in Africa: prospective systematic postmortem surveillance study. BMJ 372, n334 (2021).","journal-title":"BMJ"},{"key":"25946_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/iid3.367","volume":"9","author":"A Mveang Nzoghe","year":"2021","unstructured":"Mveang Nzoghe, A. et al. Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2. Immun. Inflamm. Dis. 9, 128\u2013133 (2021).","journal-title":"Immun. Inflamm. Dis."},{"key":"25946_CR29","doi-asserted-by":"publisher","first-page":"104645","DOI":"10.1016\/j.jcv.2020.104645","volume":"132","author":"R Batra","year":"2020","unstructured":"Batra, R. et al. A comparative evaluation between the Abbott PanbioTM COVID-19 IgG\/IgM rapid test device and Abbott ArchitectTM SARS CoV-2 IgG assay. J. Clin. Virol. 132, 104645 (2020).","journal-title":"J. Clin. Virol."},{"key":"25946_CR30","doi-asserted-by":"publisher","unstructured":"Yamayoshi, S. et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine https:\/\/doi.org\/10.1016\/j.eclinm.2021.100734 (2021).","DOI":"10.1016\/j.eclinm.2021.100734"},{"key":"25946_CR31","doi-asserted-by":"crossref","unstructured":"Sykes, W. et al. Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape and Free State provinces of South Africa in January 2021. https:\/\/www.researchsquare.com\/article\/rs-233375\/v1. (2021).","DOI":"10.21203\/rs.3.rs-233375\/v1"},{"key":"25946_CR32","unstructured":"OpenStreetMap. OpenStreetMap. https:\/\/www.openstreetmap.org\/ (2021)."},{"key":"25946_CR33","unstructured":"Institut National de la Statistique (INS) & The DHS Program (ICF). Enqu\u00eate D\u00e9mographique et de Sant\u00e9 du Cameroun (2018)."},{"key":"25946_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/oxfordjournals.aje.a112510","volume":"107","author":"WJ Rogan","year":"1978","unstructured":"Rogan, W. J. & Gladen, B. Estimating prevalence from the results of a screening test. Am. J. Epidemiol. 107, 71\u201376 (1978).","journal-title":"Am. J. Epidemiol."},{"key":"25946_CR35","doi-asserted-by":"publisher","unstructured":"Lumley, T. Analysis of complex survey samples. J. Stat. Softw. https:\/\/doi.org\/10.18637\/jss.v009.i08 (2004).","DOI":"10.18637\/jss.v009.i08"},{"key":"25946_CR36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/ije\/dyab049","volume":"50","author":"MYR Henrion","year":"2021","unstructured":"Henrion, M. Y. R. bootComb\u2014an R package to derive confidence intervals for combinations of independent parameter estimates. Int. J. Epidemiol. 50, 1071\u20131076 (2021).","journal-title":"Int. J. Epidemiol"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25946-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25946-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25946-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:51:38Z","timestamp":1669978298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25946-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["25946"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-25946-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-411135\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"11 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5851"}}